期刊
IMMUNOLOGIC RESEARCH
卷 60, 期 2-3, 页码 320-329出版社
HUMANA PRESS INC
DOI: 10.1007/s12026-014-8580-6
关键词
Intravenous immunoglobulin; IVIg; Guillain-Barre syndrome; Th1 cells; Th17 cells; Regulatory T cells
类别
资金
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Centre National de la Recherche Scientifique (CNRS)
- Universite Pierre et Marie Curie
- Universite Paris Descartes
- Journees de Neurologie de Langue Francaise
- CSL Behring France
Guillain-Barr, syndrome (GBS) is an acute, autoimmune inflammatory disorder of peripheral nervous system characterized by a severe functional motor weakness. Treatment with intravenous immunoglobulin (IVIg) is one of the approved and preferred therapeutic strategies for GBS. However, the mechanisms underlying the therapeutic benefit with IVIg in GBS are not completely understood. In the present study, we observed that GBS patients have increased frequencies of Th1 and Th17 cells, but reduced number of Foxp3(+) regulatory T cells (T-reg cells) with defective functions. We show that IVIg treatment in GBS patients results in a marked reduction in the frequency of Th1 and Th17 cells with a concomitant expansion of T-reg cells. Importantly, IVIg-expanded T-reg cells exhibited an increased T cell suppressive function. Together our results demonstrate that therapeutic benefit of IVIg in GBS patients implicates the reciprocal regulation of Th1/Th17 and T-reg cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据